Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific ADC
AMSTERDAM, Sept. 13, 2023 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases.
Advanced BioScience Laboratories (ABL), a global contract development and manufacturing organization (CDMO) and contract research organization (CRO) serving the U.S. Government and biopharmaceutical industry, was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) of the National Institutes of Health (NIH), under the Diagnostics Preclinical Services program.
ABL, a pure play Contract Development and Manufacturing Organization (CDMO) with specialized expertise in the development and manufacturing of solutions for biopharma, and RD-Biotech, a CRO/CDMO providing custom services in development and production of plasmid DNA, monoclonal antibodies and recombinant proteins, have signed a strategic partnership in Cell and Gene Therapy (C>) GMP manufacturing.
SAN DIEGO -- Over 250 Korean companies participated in this year’s BIO International Convention, the world’s largest biotechnology industry gathering that took place in person for the first time in three years.
Coave Therapeutics, a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therapies, have entered into a collaboration to develop gene therapy manufacturing processes.
PARIS and STRASBOURG, France, June 9, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therapies, today announce that they have entered into a strategic collaboration to develop gene therapy manufacturing processes. The financial terms are not disclosed.
ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.
Add Sanofi to the list of companies aiming to treat Parkinson’s disease by targeting alpha-synuclein. The Big Pharma has claimed a spot toward the back of the pack by paying $75 million upfront for the global rights to a preclinical bispecific that targets the protein.